Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Dominant Negative
100%
Hyperactivity
100%
Janus Kinase Inhibitors
100%
Janus Kinase
100%
STAT1 Pathway
100%
STAT3 mutation
100%
STAT1 Gain of Function
55%
Interferon-α (IFN-α)
33%
Ruxolitinib
33%
Targeted Treatment
22%
Patient Cells
22%
In Vivo Applications
22%
Phosphorylated STAT1
22%
AD-HIES
22%
Treatment Options
11%
Interleukin-6
11%
Gene Expression
11%
Quantitative PCR
11%
Downstream Signaling
11%
Healthy Controls
11%
Flow Cytometry
11%
Clinical Manifestations
11%
Downstream Genes
11%
Healthy Donors
11%
Autoimmune
11%
Immunoblot
11%
ELISA Method
11%
CD14+ Monocytes
11%
Autoinflammatory
11%
Janus Kinase 1 (JAK1)
11%
CD3+ Cells
11%
Associated Symptoms
11%
STAT1 Phosphorylation
11%
STAT1 Signaling
11%
Inflammatory Manifestations
11%
C-X-C Motif Chemokine 10
11%
Flow-ELISA
11%
Medicine and Dentistry
Ex Vivo
100%
Janus Kinase
100%
Hyperactivation
100%
Interferon
75%
Ruxolitinib
75%
Cytokine
50%
Targeted Therapy
50%
Janus Kinase Inhibitor
50%
Secretion (Process)
25%
Real-Time Polymerase Chain Reaction
25%
Interleukin 6
25%
Flow Cytometry
25%
Enzyme Linked Immunosorbent Assay
25%
Gene Expression
25%
Autoimmunity
25%
Immunoblotting
25%
CD3 Antigen
25%
C-X-C Motif Chemokine 10
25%
Treatment Option
25%
Biochemistry, Genetics and Molecular Biology
STAT1
100%
STAT3
100%
Janus Kinase
100%
Ruxolitinib
18%
Interferon
18%
Cytokine
12%
Janus Kinase Inhibitor
12%
Secretion (Process)
6%
Real-Time Polymerase Chain Reaction
6%
Gene Expression
6%
Autoimmunity
6%
Interleukin 6
6%
CD14
6%
C-X-C Motif Chemokine 10
6%
Flow Cytometry
6%
Immunoblotting
6%
Immunology and Microbiology
STAT3
100%
STAT1
100%
interferon
18%
Cytokine
12%
Secretion (Process)
6%
Gene Expression
6%
Real-Time Polymerase Chain Reaction
6%
Interleukin 6
6%
Autoimmunity
6%
Western Blot
6%
ELISA
6%
CD14
6%
C-X-C Motif Chemokine 10
6%
CD3 Antigen
6%